Lipocine announces positive oral brexanolone quantitative eeg results

Quantitative electroencephalogram (qeeg) in healthy subjects administered single doses of oral brexanolone, a neuroactive steroid (nas), confirmed gabaa modulation rapid and durable cns target engagement confirms effective oral delivery of bioidentical brexanolone promising results support continued development of oral brexanolone for the treatment of neuropsychiatric disorders salt lake city , oct. 10, 2024 /prnewswire/ -- lipocine inc. (nasdaq: lpcn), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced positive data from its qeeg study of its oral brexanolone, a proprietary bioidentical nas being developed for the treatment of post-partum depression (ppd). changes in spectral power (a quantitative measure of the strength or intensity of specific brain wave frequencies) are frequently used to characterize the effects of drug candidates and may have utility in indication and dose selection in cns clinical trials.
LPCN Ratings Summary
LPCN Quant Ranking